Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Mihályová · SciRah

Researcher profile · Semantic Scholar

J. Mihályová

Share profile

J. Mihályová — researcher profile on SciRah

h-index: 11
Works: 55
Citations: 562

Most-cited papers

PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017
T. Jelínek, J. Mihályová, M. Kaščák, J. Ďuraš +1 more
2017Immunology119 citations Open access
Semantic Scholar
Venetoclax: A new wave in hematooncology.
J. Mihályová, T. Jelínek, K. Growková, M. Hrdinka +2 more
2018Experimental Hematology95 citations Open access
Semantic Scholar
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Zhong-Fei Tao, Z. Chyra, Jana Kotulová, Piotr Celichowski +3 more
2024Blood Cancer Journal91 citations Open access
Semantic Scholar
Single‐agent venetoclax induces MRD‐negative response in relapsed primary plasma cell leukemia with t(11;14)
T. Jelínek, J. Mihályová, M. Kaščák, J. Ďuraš +16 more
2018American journal of hematology/oncology41 citations
Semantic Scholar
Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
K. Benková, J. Mihályová, R. Hájek, T. Jelínek
2020Blood reviews29 citations
Semantic Scholar
Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
A. Kumar, S. Atallah-Yunes, Sridevi Rajeeve, A. Abdelhak +30 more
2024Blood26 citations
Semantic Scholar
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
T. Jelínek, D. Žihala, A. Zabaleta, Ioannis V. Kostopoulos +33 more
2025Blood19 citations Open access
Semantic Scholar
Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma
T. Jelínek, Lucie Adamusova, T. Popková, Ivana Tvrdá +10 more
2018Bone Marrow Transplantation17 citations
Semantic Scholar
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort
T. Jelínek, T. Popková, J. Ďuraš, J. Mihályová +7 more
2020Hematological Oncology13 citations
Semantic Scholar
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)
M. Špaček, L. Smolej, M. Šimkovič, L. Nekvindová +19 more
2023British Journal of Haematology12 citations Open access
Semantic Scholar
CD38 targeted treatment for multiple myeloma.
T. Jelínek, J. Mihályová, R. Hájek
2018Vnitrni lekarstvi11 citations Open access
Semantic Scholar
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
J. Mihályová, K. Hradská, T. Jelínek, Benjamin Motais +2 more
2021International Journal of Molecular Sciences10 citations Open access
Semantic Scholar
Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B
Simon J. Harrison, Caroline Hasselbalch Riley, H. Mian, Andrew Spencer +15 more
2025Blood8 citations
Semantic Scholar
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma
Juan-Jose Garcés, B. Diamond, T. Ševčíková, S. Nenarokov +25 more
2025HemaSphere8 citations Open access
Semantic Scholar
Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
T. Jelínek, D. Žihala, A. Zabaleta, Ioannis V. Kostopoulos +21 more
2024Blood8 citations
Semantic Scholar
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis
M. Štork, J. Radocha, J. Mihályová, I. Špička +17 more
2025Annals of Hematology7 citations Open access
Semantic Scholar
External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score
L. Smolej, P. Turcsányi, Z. Kubová, J. Zuchnická +7 more
2020British Journal of Haematology7 citations Open access
Semantic Scholar
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group
M. Šimkovič, P. Turcsányi, M. Špaček, J. Mihályová +20 more
2023Annals of Hematology5 citations Open access
Semantic Scholar
Management of Treatment-Related Infectious Complications in High-Risk Hemato-Oncological Patients via Telemedicine
K. Hradská, T. Popková, Michaela Škorupová, J. Mihályová +4 more
2022Cancer Management and Research5 citations Open access
Semantic Scholar
Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis
R. Popat, Oliver Morjaria, C. Tan, Saad Z. Usmani +21 more
2025Blood4 citations
Semantic Scholar
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO
Gurdeep Parmar, M. Capra, Fernanda Seguro, V. Hungria +19 more
2025Blood Cancer Journal4 citations Open access
Semantic Scholar
The European CAR‐T map—Current status and future directions to improve access to CAR T‐cell therapy for hematologic malignancies
E. Pennings, F. Thielen, F. Broussais, Julio Delgado +19 more
2026HemaSphere3 citations Open access
Semantic Scholar
Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre‐Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients
O. Venglar, E. Radova, D. Žihala, Ivana Tvrdá +15 more
2025American journal of hematology/oncology3 citations Open access
Semantic Scholar
Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment
Anjana Anilkumar Sithara, V. Kapustová, D. Žihala, O. Venglar +28 more
2025Blood Cancer Discovery3 citations Open access
Semantic Scholar
Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment
D. Žihala, Anjana Anilkumar Sithara, V. Kapustová, O. Venglar +17 more
2024Blood3 citations
Semantic Scholar
Osteolytic bone lesions, hypercalcemia and paraprotein, but not a myeloma: case report and review of literature.
K. Hradská, T. Jelínek, J. Ďuraš, J. Mihályová +6 more
2020Vnitrni lekarstvi3 citations Open access
Semantic Scholar
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis
C. Tan, Saad Z. Usmani, A. Derkach, Andre De Menezes Silva Corraes +27 more
2026Blood Advances2 citations Open access
Semantic Scholar
Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma
T. Jelínek, S. Nenarokov, T. Ševčíková, E. Radova +15 more
2024Blood2 citations
Semantic Scholar
Immune Response in 465 Hematological Patients Vaccinated with mRNA Vaccine Against SARS-CoV-2: A Single Centre Experience
Ondrej Šušol, B. Hájková, T. Jelínek, J. Mihályová +6 more
2021Social Science Research Network2 citations Open access
Semantic Scholar
Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence
O. Venglar, V. Hrabčáková, Ondřej Souček, Kamila Kutejova +15 more
2025Blood1 citations
Semantic Scholar
New therapeutic options and trends in the treatment of multiple myelom
R. Hájek, L. Muroňová, J. Mihályová, Michaela Horňáková +3 more
2025Vnitrni lekarstvi1 citations
Semantic Scholar
One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic
Ondrej Šušol, Barbora Šušolová, O. Klempíř, Milan Navrátil +20 more
2024Cancer Medicine1 citations
Semantic Scholar
Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
O. Venglar, E. Radova, D. Žihala, Ivana Tvrdá +13 more
2024Blood1 citations
Semantic Scholar
Characterization of Infectious Complications during the Expected Duration of Cytokine Release Syndrome (CRS) in Patients Receiving CAR T Cell Therapy – Are We over-Treating with Anti-Microbials?
J. Mihályová, Sana Ahmad, Shivani Handa, Jacques Azzi +6 more
2024Transplantation and Cellular Therapy1 citations Open access
Semantic Scholar
Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment
T. Popková, K. Hradská, J. Mihályová, Michaela Škorupová +9 more
2019Blood1 citations Open access
Semantic Scholar
Ibrutinib v hematoonkologii
J. Mihályová, J. Ďuraš, J. Zuchnická, M. Kaščák +1 more
20161 citations Open access
Semantic Scholar
Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group
J. Mihályová, A. Panovská, M. Šimkovič, L. Smolej +13 more
2026Annals of Hematology0 citations Open access
Semantic Scholar
Comparison of the HemoScreen Point-Of-Care Haematology Analyser With Sysmex XN, Beckman Coulter DxH 560 and HORIBA Yumizen H550 in Patients With Abnormal Blood Counts.
K. Hradská, M. Pulcer, Michaela Škorupová, T. Popková +10 more
2026International Journal of Laboratory Hematology0 citations Open access
Semantic Scholar
PA-034 Anti-BCMA Immunotherapies Deplete Plasmacytoid Dendritic Cells and Impair Antiviral Immunity in Multiple Myeloma
O. Venglar, E. Radova, M. Warmuzová, D. Bilek +18 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
P25 | REAL-WORLD OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA: EVIDENCE SUPPORTING BORTEZOMIB–LENALIDOMIDE–DEXAMETHASONE AS A PREFERRED REGIMEN WITHOUT ANTI-CD38 ANTIBODIES
A. Jungova, M. Štork, I. Špička, J. Radocha +27 more
2026Haematologica0 citations Open access
Semantic Scholar
Role B-cell maturation antigenu v léčbě mnohočetného myelomu
Vilímová, K., Kušnierová, P. +2 more
2026Klinicka Biochemie a Metabolismus0 citations
Semantic Scholar
B03 | TRANSCRIPTOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN MULTIPLE MYELOMA REVEALS EGRESSION-ASSOCIATED PROFILE RELATED TO CTC BURDEN
D. Bilek, E. Radova, V. Kapustová, M. Warmuzová +18 more
2026Haematologica0 citations Open access
Semantic Scholar
Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma.
Gurdeep Parmar, M. Capra, V. Hungria, Fernanda Seguro +18 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations Open access
Semantic Scholar
Anti‐BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma
O. Venglar, E. Radova, M. Warmuzová, D. Bilek +19 more
2026HemaSphere0 citations Open access
Semantic Scholar
Impact of antibiotic timing on survival outcomes in CD19 and BCMA CAR-T cell therapy
Serena Tharakan, Patrick Crorkin, Sana Ahmad, J. Mihályová +8 more
2025Blood0 citations
Semantic Scholar
CT-1192: Characterization of Infectious Complications Following CAR T-Cell Therapy and the Need for Antibiotic Treatment During the Expected Period of Cytokine Release Syndrome
Patrick Crorkin, Serena Tharakan, Sana Ahmad, J. Mihályová +8 more
2025Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden
D. Bilek, E. Radova, V. Kapustová, O. Venglar +17 more
2025Blood0 citations
Semantic Scholar
Guidelines for the management of adverse events following CD19 CAR-T cell therapy in adult patients with lymphomas and acute lymphoblastic leukaemia – consensus of expert panel from certified centres in Czechia and Slovakia for 2025
František Folber, Flóra Benkő, B. Čemusová, Jan Vydra +20 more
2025Transfuze a hematologie dnes0 citations
Semantic Scholar
High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy
O. Venglar, D. Bilek, E. Radova, V. Kapustová +17 more
2025Blood0 citations
Semantic Scholar
POSTER: CT-1192 Characterization of Infectious Complications Following Car T-Cell Therapy and the Need for Antibiotic Treatment During the Expected Period of Cytokine Release Syndrome
Patrick Crorkin, Serena Tharakan, Sana Ahmad, J. Mihályová +8 more
2025Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Popková×23
Invite
T. Popková — researcher profile on SciRah
T. Jelínek×18
Invite
T. Jelínek — researcher profile on SciRah
H. Plonkova×16
Invite
H. Plonkova — researcher profile on SciRah
L. Muroňová×16
Invite
L. Muroňová — researcher profile on SciRah

L. Broskevicova

×15

Invite

L. Broskevicova — researcher profile on SciRah

Invite

D. Žihala — researcher profile on SciRah

Invite

O. Venglar — researcher profile on SciRah

T. Ševčíková×14

Invite

T. Ševčíková — researcher profile on SciRah

Invite

R. Hájek — researcher profile on SciRah

Invite

R. Hájek — researcher profile on SciRah

Invite

E. Radova — researcher profile on SciRah

T. Jelínek×12

Invite

T. Jelínek — researcher profile on SciRah